OBJECTIVE: To compare interval breast cancer rates (ICR) between a biennial organized screening programme in Norway and annual opportunistic screening in North Carolina (NC) for different conceptualizations of interval cancer. SETTING: Two regions with different screening practices and performance. METHODS: 620,145 subsequent screens (1996-2002) performed in women aged 50-69 and 1280 interval cancers were analysed. Various definitions and quantification methods for interval cancers were compared. RESULTS: ICR for one year follow-up were lower in Norway compared with NC both when the rate was based on all screens (0.54 versus 1.29 per 1000 screens), negative final assessments (0.54 versus 1.29 per 1000 screens), and negative screening assessments (0.53 versus 1.28 per 1000 screens). The rate of ductal carcinoma in situ was significantly lower in Norway than in NC for cases diagnosed in both the first and second year after screening. The distributions of histopathological tumour size and lymph node involvement in invasive cases did not differ between the two regions for interval cancers diagnosed during the first year after screening. In contrast, in the second year after screening, tumour characteristics remained stable in Norway but became prognostically more favorable in NC. CONCLUSION: Even when applying a common set of definitions of interval cancer, the ICR was lower in Norway than in NC. Different definitions of interval cancer did not influence the ICR within Norway or NC. Organization of screening and screening performance might be major contributors to the differences in ICR between Norway and NC.
OBJECTIVE: To compare interval breast cancer rates (ICR) between a biennial organized screening programme in Norway and annual opportunistic screening in North Carolina (NC) for different conceptualizations of interval cancer. SETTING: Two regions with different screening practices and performance. METHODS: 620,145 subsequent screens (1996-2002) performed in women aged 50-69 and 1280 interval cancers were analysed. Various definitions and quantification methods for interval cancers were compared. RESULTS: ICR for one year follow-up were lower in Norway compared with NC both when the rate was based on all screens (0.54 versus 1.29 per 1000 screens), negative final assessments (0.54 versus 1.29 per 1000 screens), and negative screening assessments (0.53 versus 1.28 per 1000 screens). The rate of ductal carcinoma in situ was significantly lower in Norway than in NC for cases diagnosed in both the first and second year after screening. The distributions of histopathological tumour size and lymph node involvement in invasive cases did not differ between the two regions for interval cancers diagnosed during the first year after screening. In contrast, in the second year after screening, tumour characteristics remained stable in Norway but became prognostically more favorable in NC. CONCLUSION: Even when applying a common set of definitions of interval cancer, the ICR was lower in Norway than in NC. Different definitions of interval cancer did not influence the ICR within Norway or NC. Organization of screening and screening performance might be major contributors to the differences in ICR between Norway and NC.
Authors: Samantha Puvanesarajah; Sarah J Nyante; Cherie M Kuzmiak; Mengjie Chen; Chiu-Kit Tse; Xuezheng Sun; Emma H Allott; Erin L Kirk; Lisa A Carey; Charles M Perou; Andrew F Olshan; Louise M Henderson; Melissa A Troester Journal: Cancer Prev Res (Phila) Date: 2018-04-05
Authors: Katja Kemp Jacobsen; Ellen S O'Meara; Dustin Key; Diana S M Buist; Karla Kerlikowske; Ilse Vejborg; Brian L Sprague; Elsebeth Lynge; My von Euler-Chelpin Journal: Int J Cancer Date: 2015-06-01 Impact factor: 7.396
Authors: Benjamin Hinton; Lin Ma; Amir Pasha Mahmoudzadeh; Serghei Malkov; Bo Fan; Heather Greenwood; Bonnie Joe; Vivian Lee; Fredrik Strand; Karla Kerlikowske; John Shepherd Journal: Med Phys Date: 2019-02-14 Impact factor: 4.071
Authors: Valérie D V Sankatsing; Jacques Fracheboud; Linda de Munck; Mireille J M Broeders; Nicolien T van Ravesteyn; Eveline A M Heijnsdijk; André L M Verbeek; Johannes D M Otten; Ruud M Pijnappel; Sabine Siesling; Harry J de Koning Journal: BMC Cancer Date: 2018-03-05 Impact factor: 4.430
Authors: Laia Domingo; Solveig Hofvind; Rebecca A Hubbard; Marta Román; David Benkeser; Maria Sala; Xavier Castells Journal: Eur Radiol Date: 2015-11-11 Impact factor: 5.315